Literature DB >> 19605976

Two-year follow-up of thirty-two non-functional benign adrenal incidentalomas.

H Yilmaz1, N B Tütüncü, M Sahin.   

Abstract

OBJECTIVE: To evaluate the risk of developing endocrine hyperactivity and carcinoma during a period of up to 5 yr in patients with apparently benign and non-functioning adrenal incidentalomas. PATIENTS AND METHODS: Thirty-two patients (mean age: 57.0+/-8.3 yr) were investigated in a prospective follow-up study for a median time of 24 months. Twenty-eight patients had unilateral and 4 had bilateral masses. Initial average mass diameter was 17.47+/-6.60 mm. All patients were followed up yearly by physical examination, metabolic parameters, hormonal evaluation [morning cortisol after 3-mg dexamethasone suppression, urinary metanephrines, and upright aldosterone/ plasma renin activity (PRA)].
RESULTS: Among the clinical characteristics, 48% of patients were obese, 20% were hypertensive, 13 had Type 2 diabetes and impaired glucose tolerance. During follow-up period no significant change in the functional status was observed and nomalignant transformation occurred. Only 1 patient developed subclinical Cushing's syndrome at the end of the 1st year and referred to surgery. Change in mass size was correlated with homeostasis model assessment of insulin resistance (p=0.002), upright aldosterone/ PRA (p=0.041), cortisol after dexamethasone suppression (p=0.048) and 24-h urinary normetanephrine (p=0.005) levels. Gender, body mass index, glucose metabolism, and blood pressure were not found to be correlated with change in mass size and functional status.
CONCLUSIONS: Due to the extremely low risk of developing malignancy during up to 5 yr of follow-up, conservative approach for the management of adrenal incidentalomas is thought to be appropriate. However, possibility of evolution to hormonal hypersecretion makes long-term follow-up of 2-to-5 yr seems to be obligatory.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19605976     DOI: 10.1007/BF03345772

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  27 in total

1.  Subclinical Cushing's syndrome in patients with adrenal incidentaloma: clinical and biochemical features.

Authors:  R Rossi; L Tauchmanova; A Luciano; M Di Martino; C Battista; L Del Viscovo; V Nuzzo; G Lombardi
Journal:  J Clin Endocrinol Metab       Date:  2000-04       Impact factor: 5.958

Review 2.  Management approaches to adrenal incidentalomas (adrenalomas). A view from Athens, Greece.

Authors:  D A Linos
Journal:  Endocrinol Metab Clin North Am       Date:  2000-03       Impact factor: 4.741

3.  Adrenal incidentalomas: a manifestation of the metabolic syndrome?

Authors:  M Reincke; M Fassnacht; S Väth; P Mora; B Allolio
Journal:  Endocr Res       Date:  1996-11       Impact factor: 1.720

4.  Natural course of adrenal incidentalomas: seven-year follow-up study.

Authors:  J Sirén; P Tervahartiala; A Sivula; R Haapiainen
Journal:  World J Surg       Date:  2000-05       Impact factor: 3.352

5.  Long-term follow-up study of patients with adrenal incidentalomas.

Authors:  Rossella Libè; Chiara Dall'Asta; Laura Barbetta; Andrea Baccarelli; Paolo Beck-Peccoz; Bruno Ambrosi
Journal:  Eur J Endocrinol       Date:  2002-10       Impact factor: 6.664

6.  Body composition and metabolic features in women with adrenal incidentaloma or Cushing's syndrome.

Authors:  G G Garrapa; P Pantanetti; G Arnaldi; F Mantero; E Faloia
Journal:  J Clin Endocrinol Metab       Date:  2001-11       Impact factor: 5.958

7.  Management of the clinically inapparent adrenal mass ("incidentaloma").

Authors:  Melvin M Grumbach; Beverly M K Biller; Glenn D Braunstein; Karen K Campbell; J Aidan Carney; Paul A Godley; Emily L Harris; Joseph K T Lee; Yolanda C Oertel; Mitchell C Posner; Janet A Schlechte; H Samuel Wieand
Journal:  Ann Intern Med       Date:  2003-03-04       Impact factor: 25.391

Review 8.  Adrenal incidentaloma: evaluation and management.

Authors:  P K Singh; H N Buch
Journal:  J Clin Pathol       Date:  2008-11       Impact factor: 3.411

9.  Adrenal incidentalomas, 2003 to 2005: experience after publication of the National Institutes of Health consensus statement.

Authors:  Leslie S Eldeiry; Jeffrey R Garber
Journal:  Endocr Pract       Date:  2008-04       Impact factor: 3.443

10.  Adrenal incidentalomas: diagnostic evaluation and long-term follow-up.

Authors:  Lucio Vilar; Maria da Conceição Freitas; Viviane Canadas; José Luciano Albuquerque; Carlos A Botelho; Célia S Egito; Maria Juliana Arruda; Lidiane Moura e Silva; Carlos E Coelho; Luiz Augusto Casulari; Luciana A Naves
Journal:  Endocr Pract       Date:  2008-04       Impact factor: 3.443

View more
  5 in total

1.  The presence of nonfunctioning adrenal incidentalomas increases arterial hypertension frequency and severity, and is associated with cortisol levels after dexamethasone suppression test.

Authors:  Mariana Arruda; Emanuela Mello Ribeiro Cavalari; Marcela Pessoa de Paula; Felipe Fernandes Cordeiro de Morais; Guilherme Furtado Bilro; Maria Caroline Alves Coelho; Nathalie Anne de Oliveira E Silva de Morais; Diana Choeri; Aline Moraes; Leonardo Vieira Neto
Journal:  J Hum Hypertens       Date:  2017-11-24       Impact factor: 3.012

Review 2.  Endocrine incidentalomas--challenges imposed by incidentally discovered lesions.

Authors:  Dimitra A Vassiliadi; Stylianos Tsagarakis
Journal:  Nat Rev Endocrinol       Date:  2011-06-28       Impact factor: 43.330

3.  Cortisol level after dexamethasone suppression test in patients with non-functioning adrenal incidentaloma is positively associated with the duration of reactive hyperemia response on microvascular bed.

Authors:  M P de Paula; A B Moraes; M das Graças Coelho de Souza; E M R Cavalari; R C Campbell; G da Silva Fernandes; M L F Farias; L M C Mendonça; M Madeira; E Bouskela; L G Kraemer-Aguiar; L Vieira Neto
Journal:  J Endocrinol Invest       Date:  2020-07-19       Impact factor: 4.256

4.  Adrenalectomy improves blood pressure control in nonfunctioning adrenal incidentalomas and glycemic and lipid control in patients with autonomous cortisol secretion.

Authors:  Marta Araujo-Castro; César Mínguez Ojeda; María Noelia Sánchez Ramírez; Victoria Gómez Dos Santos; Eider Pascual-Corrrales; María Fernández-Argüeso
Journal:  Endocrine       Date:  2022-06-25       Impact factor: 3.925

5.  NEW BIOMARKERS TO PREDICT CARDIOVASCULAR RISK IN PATIENTS WITH ADRENAL INCIDENTALOMA; IRISIN AND NESFATIN-1.

Authors:  M Can; M Kocabaş; M Karaköse; Y Alsancak; F H Yerlikaya; H Caliskan Burgucu; I Cordan; C Kadiyoran; M Kulaksızoğlu; F Karakurt
Journal:  Acta Endocrinol (Buchar)       Date:  2022 Apr-Jun       Impact factor: 1.104

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.